ReviewReviews in cardiovascular medicine2025
Platelet-Rich Plasma in Cardiovascular Regeneration: Mechanistic Insights, Technological Innovations, and Future Directions.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microvascular Health as a Key Determinant of Organismal Aging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP), an autologous concentrate of platelets and bioactive molecules, has emerged as a promising regenerative therapy in cardiovascular medicine. The potential of PRP extends beyond hemostasis to include myocardial repair, angiogenesis, and immunomodulation. This review explores the biological mechanisms of PRP, its clinical applications in ischemic heart disease, peripheral artery disease, and inflammatory cardiopathies, and addresses challenges in standardization and translation. PRP exerts therapeutic effects through three primary mechanisms: promoting angiogenesis by stimulating endothelial cell proliferation and migration, exerting anti-inflammatory and immunomodulatory effects by balancing cytokine release, and enhancing myocardial repair and functional recovery by activating resident cardiac progenitor cells. Despite the promise of PRP, challenges such as variability in PRP composition due to differences in preparation methods and safety concerns remain. To overcome these barriers, precision engineering and cross-disciplinary integration are crucial. Innovations such as nanotechnology-driven targeted delivery systems and clustered regularly interspaced short palindromic repeats (CRISPR)-edited exosomes offer mechanism-specific interventions. Artificial intelligence (AI)-driven approaches utilizing single-cell RNA sequencing data can enable personalized treatment strategies, while closed-loop systems minimize batch-to-batch variability. Collaborative efforts between clinicians, engineers, and regulators are essential to establish global standards for exosome characterization. PRP-based therapies hold immense promise for revolutionizing cardiovascular regenerative medicine by modulating angiogenesis, inflammation, and myocardial repair. By embracing these advanced technologies and interdisciplinary approaches, PRP can transition from an empirical treatment to a data-driven, mechanism-specific intervention, ultimately redefining the future of cardiovascular care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.